A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
PHASE2
This is a dose-ranging study designed to investigate the efficacy and safet...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
PHASE1
A multicenter clinical study to evaluate the safety, PK characteristics, im...